Novel Drugs for Treatment of Neurodegeneration of the Eye and Brain

• Our therapeutic approach is unique in several ways: Our assets GAL-101 and GAL-201 are small, well tolerated molecules, that can reach their target via eye drops or oral delivery
• Their administration is noninvasive: better suited to long-term therapy than injections
• They have been rationally designed to bind only to misfolded monomers of Aβ, thereby preventing them from forming toxic oligomers
• They effectively block formation of all toxic oligomers of Aβ, without disturbing normal neuronal function
• They have the advantage of being a small molecule and block the formation of all forms of toxic oligomers at source.

Antibodies

• In contrast antibodies eliminate toxic oligomers only after their formation, require parenteral administration and have poor access to the CNS. In addition, first generation antibodies target all forms of Aβ and thereby harm normal synaptic function. The more recent oligomer specific antibodies only target subsets of Aβ oligomers due to their epitope specificity.

Our Products